Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse–Berenice-78 Trypanosoma cruzi Strain Model
Suzana Marques de Jesus, Leonardo Pinto, Fernanda de Lima Moreira, Glauco Henrique Balthazar Nardotto, Rodrigo Cristofoletti, Luísa Perin, Kátia da Silva Fonseca, Pauliana Barbêdo, Lorena Cera Bandeira, Paula Melo de Abreu Vieira, Cláudia Martins Carneiro
Abstract
ratios) of brain, colon, and heart by 1.6-, 3.25-, and 3-fold, respectively. The experimental chronic Chagas disease inflammation-mediated changes in the regulation of membrane transporters probably influence the benznidazole pharmacokinetics and the extent of benznidazole exposure in tissues. These results advise for potential alterations in benznidazole pharmacokinetics in chronic Chagas disease patients with possibilities of changes in the standard dosing regimen.
Topics & Concepts
BenznidazoleTrypanosoma cruziChagas diseasePharmacokineticsDosingPharmacologyBiologyMedicineVirologyWorld Wide WebParasite hostingComputer scienceTrypanosoma species research and implicationsResearch on Leishmaniasis StudiesSynthesis and Biological Evaluation